These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 30442716)

  • 21. A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis.
    Khoo JK; Montgomery AB; Otto KL; Surber M; Faggian J; Lickliter JD; Glaspole I
    J Aerosol Med Pulm Drug Deliv; 2020 Feb; 33(1):15-20. PubMed ID: 30698487
    [No Abstract]   [Full Text] [Related]  

  • 22. Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients.
    Fournier D; Jouneau S; Bouzillé G; Polard E; Osmont MN; Scailteux LM
    Pulm Pharmacol Ther; 2022 Oct; 76():102149. PubMed ID: 35918026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
    Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
    Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
    Noor S; Nawaz S; Chaudhuri N
    Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study.
    Moor CC; Mostard RLM; Grutters JC; Bresser P; Aerts JGJV; Dirksen CD; Kimman ML; Wijsenbeek MS
    Respir Res; 2020 Jul; 21(1):196. PubMed ID: 32703201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
    Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Shin Y; Wakamatsu I; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration.
    Ikeda S; Sekine A; Baba T; Kato T; Katano T; Tabata E; Shintani R; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
    Medicine (Baltimore); 2022 Jun; 101(22):e29232. PubMed ID: 35665728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis.
    Perelas A; Glennie J; van Kerkhove K; Li M; Scheraga RG; Olman MA; Culver DA
    Pulm Pharmacol Ther; 2019 Dec; 59():101839. PubMed ID: 31518649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
    Belhassen M; Dalon F; Nolin M; Van Ganse E
    Respir Res; 2021 May; 22(1):135. PubMed ID: 33947414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients.
    Proesmans VLJ; Drent M; Elfferich MDP; Wijnen PAHM; Jessurun NT; Bast A
    Lung; 2019 Oct; 197(5):551-558. PubMed ID: 31440832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis.
    Corral M; Chang E; Broder MS; Gokhale S; Reddy SR
    J Comp Eff Res; 2020 Sep; 9(13):933-943. PubMed ID: 32851849
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.
    Rochwerg B; Neupane B; Zhang Y; Garcia CC; Raghu G; Richeldi L; Brozek J; Beyene J; Schünemann H
    BMC Med; 2016 Feb; 14():18. PubMed ID: 26843176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone.
    Lacedonia D; Correale M; Tricarico L; Scioscia G; Stornelli SR; Simone F; Casparrini M; Brunetti ND; Foschino Barbaro MP
    Intern Emerg Med; 2022 Apr; 17(3):815-822. PubMed ID: 34787802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The safety of new drug treatments for idiopathic pulmonary fibrosis.
    Fletcher S; Jones MG; Spinks K; Sgalla G; Marshall BG; Limbrey R; Richeldi L
    Expert Opin Drug Saf; 2016 Nov; 15(11):1483-1489. PubMed ID: 27532218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment.
    Cerri S; Monari M; Guerrieri A; Donatelli P; Bassi I; Garuti M; Luppi F; Betti S; Bandelli G; Carpano M; Bacchi Reggiani ML; Tonelli R; Clini E; Nava S
    Respir Med; 2019 Nov; 159():105803. PubMed ID: 31670147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent trends in pirfenidone and nintedanib use for idiopathic pulmonary fibrosis in Australia.
    Cox IA; de Graaff B; Corte TJ; Glaspole I; Chambers DC; Moodley Y; Teoh A; Walters EH; Palmer AJ
    Aust Health Rev; 2021 Dec; 45(6):718-727. PubMed ID: 34706811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nintedanib for Idiopathic Pulmonary Fibrosis.
    Tepede A; Yogaratnam D
    J Pharm Pract; 2019 Apr; 32(2):199-206. PubMed ID: 29017422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An updated safety review of the drug treatments for idiopathic pulmonary fibrosis.
    Sgalla G; Comes A; Richeldi L
    Expert Opin Drug Saf; 2021 Sep; 20(9):1035-1048. PubMed ID: 33881959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
    Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
    Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.